Medical advances are often the product of cooperation and the pooling of resources. One such partnership between Siemens subsidiary PETNET Solutions and Avid Radiopharmaceuticals has yielded the first shipment of a new molecular imaging agent that will assist researchers in their understanding of Alzheimer’s disease.
PETNET manufactured the Avid-developed biomarker, Florbetapir F18, at its U.S. facility for use in PET imaging of _-amyloid deposits in the brain, a key pathological component of Alzheimer’s disease.
According to a PETNET press release, Florbetapir is currently being evaluated in clinical studies of patients with suspected Alzheimer’s disease or mild cognitive impairment in the United States and the European Union.
Avid’s Florbetapir was the first β-amyloid imaging compound to enter multi-center, IND clinical studies in the United States, and has been evaluated in more than a dozen trials that included patients with both normal cognitive functioning and Alzheimer’s dementia. The biomarker is currently being evaluated in a Phase III registration study.
(Source: Press Release)
